Emerging trends in surgical and adjuvant radiation therapies among women diagnosed with ductal carcinoma in situ

Cancer

Volumn 122, Issue 18, 2016, Pages 2810-2818

  Shiyanbola, Oyewale O ^a   Sprague, Brian L ^b,c   Hampton, John M ^a   Dittus, Kim ^c   James, Ted A ^b,c   Herschorn, Sally ^b,c   Gangnon, Ronald E ^a,d   Weaver, Donald L ^b,c   Trentham Dietz, Amy ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

^b UNIVERSITY OF VERMONT   (United States)

^c UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

breast cancer; ductal carcinoma in situ; mastectomy; radiation; reconstruction

Indexed keywords

ADJUVANT RADIOTHERAPY; ADULT; AFRICAN; AGED; ARTICLE; BREAST RECONSTRUCTION; BREAST SURGERY; ETHNIC DIFFERENCE; EUROPEAN; FEMALE; GEOGRAPHIC DISTRIBUTION; HEALTH CARE UTILIZATION; HISPANIC; HUMAN; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MASTECTOMY; PARTIAL MASTECTOMY; PRIORITY JOURNAL; RISK REDUCTION; TREND STUDY;

EID: 84985903287     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.30105     Document Type: Article

References (46)

1. Allegra CJ, Aberle DR, Ganschow P, et al. NIH state-of-the-science conference statement: diagnosis and management of ductal carcinoma in situ (DCIS). NIH Consens State Sci Statements. 2009;26:1–27.
2. Arpino G, Laucirica R, Elledge RM. Premalignant and in situ breast disease: biology and clinical implications. Ann Intern Med. 2005;143:446–457.
3. Ernster VL, Barclay J. Increases in ductal carcinoma in situ (DCIS) of the breast in relation to mammography: a dilemma. J Natl Cancer Inst Monogr. 1997;1997:151–156.
4. Virnig BA, Tuttle TM, Shamliyan T, Kane RL. Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes. J Natl Cancer Inst. 2010;102:170–178.
5. Ernster VL, Barclay J, Kerlikowske K, Wilkie H, Ballard-Barbash R. Mortality among women with ductal carcinoma in situ of the breast in the population-based Surveillance, Epidemiology and End Results program. Arch Intern Med. 2000;160:953–958.
6. National Comprehensive Cancer Network. Breast cancer: NCCN guidelines for patients, version 2.2011. http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed April 30, 2014.
7. Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet. 1999;353:1993–2000.
8. Baxter NN, Virnig BA, Durham SB, Tuttle TM. Trends in the treatment of ductal carcinoma in situ of the breast. J Natl Cancer Inst. 2004;96:443–448.
9. Joslyn SA. Ductal carcinoma in situ: trends in geographic, temporal, and demographic patterns of care and survival. Breast J. 2006;12:20–27.
10. Greenberg CC, Lipsitz SR, Hughes ME, et al. Institutional variation in the surgical treatment of breast cancer: a study of the NCCN. Ann Surg. 2011;254:339–345.
11. Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347:1233–1241.
12. King TA, Sakr R, Patil S, et al. Clinical management factors contribute to the decision for contralateral prophylactic mastectomy. J Clin Oncol. 2011;29:2158–2164.
13. Arrington AK, Jarosek SL, Virnig BA, Habermann EB, Tuttle TM. Patient and surgeon characteristics associated with increased use of contralateral prophylactic mastectomy in patients with breast cancer. Ann Surg Oncol. 2009;16:2697–2704.
14. Fedeli U, Fedewa SA, Ward EM. Treatment of muscle invasive bladder cancer: evidence from the National Cancer Database, 2003 to 2007. J Urol. 2011;185:72–78.
15. Nielsen ME, Mallin K, Weaver MA, et al. The association of hospital volume with conditional 90-day mortality after cystectomy: an analysis of the National Cancer Database. BJU Int. 2014;114:46–55.
16. Fritz A, Percy C, Jack A, et al. International Classification of Diseases for Oncology. Geneva, Switzerland: World Health Organization; 2000.
17. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Manual. New York, NY: Springer; 2010.
18. Surveillance, Epidemiology, and End Results Program. Standard populations—19 age groups: US standard population 1940-2000. http://seer.cancer.gov/stdpopulations/stdpop.19ages.html. Accessed June 2, 2015.
19. Mahmood U, Hanlon AL, Koshy M, et al. Increasing national mastectomy rates for the treatment of early stage breast cancer. Ann Surg Oncol. 2013;20:1436–1443.
20. McGuire KP, Santillan AA, Kaur P, et al. Are mastectomies on the rise? A 13-year trend analysis of the selection of mastectomy versus breast conservation therapy in 5865 patients. Ann Surg Oncol. 2009;16:2682–2690.
21. Poggi MM, Danforth DN, Sciuto LC, et al. Eighteen-year results in the treatment of early breast carcinoma with mastectomy versus breast conservation therapy: the National Cancer Institute randomized trial. Cancer. 2003;98:697–702.
22. Worni M, Akushevich I, Greenup R, et al. Trends in treatment patterns and outcomes for ductal carcinoma in situ. J Natl Cancer Inst. 2015;107:djv263.
23. Bickell NA, LePar F, Wang JJ, Leventhal H. Lost opportunities: physicians' reasons and disparities in breast cancer treatment. J Clin Oncol. 2007;25:2516–2521.
24. Fontana V, Castro T, Polynice A. Preferences of healthy inner city women and the surgical treatment of early stage breast cancer. Am Surg. 2007;73:215–221.
25. Baldwin LM, Patel S, Andrilla CH, Rosenblatt RA, Doescher MP. Receipt of recommended radiation therapy among rural and urban cancer patients. Cancer. 2012;118:5100–5109.
26. Nattinger AB, Kneusel RT, Hoffmann RG, Gilligan MA. Relationship of distance from a radiotherapy facility and initial breast cancer treatment. J Natl Cancer Inst. 2001;93:1344–1346.
27. Wang HT, Barone CM, Steigelman MB, et al. Aesthetic outcomes in breast conservation therapy. Aesthet Surg J. 2008;28:165–170.
28. Duggal CS, Metcalfe D, Sackeyfio R, Carlson GW, Losken A. Patient motivations for choosing postmastectomy breast reconstruction. Ann Plast Surg. 2013;70:574–580.
29. Wilkins EG, Cederna PS, Lowery JC, et al. Prospective analysis of psychosocial outcomes in breast reconstruction: one-year postoperative results from the Michigan Breast Reconstruction Outcome Study. Plast Reconstr Surg. 2000;106:1014–1025.
30. Yang RL, Newman AS, Lin IC, et al. Trends in immediate breast reconstruction across insurance groups after enactment of breast cancer legislation. Cancer. 2013;119:2462–2468.
31. Morrow M, Mujahid M, Lantz PM, et al. Correlates of breast reconstruction: results from a population-based study. Cancer. 2005;104:2340–2346.
32. Kruper L, Xu X, Henderson K, Bernstein L. Disparities in reconstruction rates after mastectomy for ductal carcinoma in situ (DCIS): patterns of care and factors associated with the use of breast reconstruction for DCIS compared with invasive cancer. Ann Surg Oncol. 2011;18:3210–3219.
33. Grimmer L, Liederbach E, Velasco J, Pesce C, Wang CH, Yao K. Variation in contralateral prophylactic mastectomy rates according to racial groups in young women with breast cancer, 1998 to 2011: a report from the National Cancer Data Base. J Am Coll Surg. 2015;221:187–196.
34. Kurian AW. BRCA1 and BRCA2 mutations across race and ethnicity: distribution and clinical implications. Curr Opin Obstet Gynecol. 2010;22:72–78.
35. Rao SR, Breen N, Graubard BI. Trends in black-white disparities in breast and colorectal cancer screening rates in a changing screening environment: the Peters-Belson approach using United States National Health Interview Surveys 2000–2010. Med Care. 2016;54:133–139.
36. Wharam JF, Landon BE, Xu X, Zhang F, Ross-Degnan D. National trends and disparities in mammography among commercially insured women, 2001-2010. J Public Health Manag Pract. 2015;21:426–432.
37. Levinson W, Kao A, Kuby A, Thisted RA. Not all patients want to participate in decision making. A national study of public preferences. J Gen Intern Med. 2005;20:531–535.
38. National Center for Education Statistics. The condition of education: educational attainment. https://nces.ed.gov/programs/coe/indicator_caa.asp. Accessed November 29, 2015.
39. Hawley ST, Lantz PM, Janz NK, et al. Factors associated with patient involvement in surgical treatment decision making for breast cancer. Patient Educ Couns. 2007;65:387–395.
40. Hawley ST, Griggs JJ, Hamilton AS, et al. Decision involvement and receipt of mastectomy among racially and ethnically diverse breast cancer patients. J Natl Cancer Inst. 2009;101:1337–1347.
41. Neff PT, Bear HD, Pierce CV, et al. Long-term results of breast conservation therapy for breast cancer. Ann Surg. 1996;223:709–716.
42. Kruper L, Xu XX, Henderson K, Bernstein L, Chen SL. Utilization of mastectomy and reconstruction in the outpatient setting. Ann Surg Oncol. 2013;20:828–835.
43. Pesce C, Liederbach E, Wang C, Lapin B, Winchester DJ, Yao K. Contralateral prophylactic mastectomy provides no survival benefit in young women with estrogen receptor–negative breast cancer. Ann Surg Oncol. 2014;21:3231–3239.
44. Jatoi I, Parsons HM. Contralateral prophylactic mastectomy and its association with reduced mortality: evidence for selection bias. Breast Cancer Res Treat. 2014;148:389–396.
45. Evans DG, Ingham SL, Baildam A, et al. Contralateral mastectomy improves survival in women with BRCA1/2-associated breast cancer. Breast Cancer Res Treat. 2013;140:135–142.
46. Feinstein AJ, Soulos PR, Long JB, et al. Variation in receipt of radiation therapy after breast-conserving surgery: assessing the impact of physicians and geographic regions. Med Care. 2013;51:330–338.